G1 Therapeutics Phase 3 Trial Update: Market Response
Shares of G1 Therapeutics plunged 46% after disappointing results from their Phase 3 trilaciclib combination trial for triple-negative breast cancer. ...
- Latest
- Trending
Shares of G1 Therapeutics plunged 46% after disappointing results from their Phase 3 trilaciclib combination trial for triple-negative breast cancer. ...
Shares of industrial & transportation companies rise as optimism grows over economic outlook. Michelin plans share repurchase. Digital freight broker ...
Federal Realty Investment Trust reports a decrease in net income for 2023, but shows growth in funds from operations and ...
Optex Systems Holdings, Inc. reports impressive surge in revenue and profit for Q4 2023, with total revenues up 72.5% and ...
Apps are offering solutions for dating situations gone wrong, providing features such as fake calls and discreet messaging to ensure ...
Lattice Semiconductor reported disappointing Q4 FY2023 results, with a decline in revenue and missed sales expectations. Despite this, the company ...
Cadence Design Systems reports strong Q4 results with record revenue, but stock drops on soft revenue guidance for next quarter.
Amazon secures exclusive streaming rights for an NFL playoff game, further solidifying its dominance in the streaming market and highlighting ...
Bitwise Asset Management predicts strong growth for spot Bitcoin ETFs as demand surges and the price of Bitcoin hits $50,000. ...
Jeff Bezos aims to reclaim the title of the world's richest person from Elon Musk by selling up to 50 ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.